Austin Walne
Partner @ Artis Ventures
San Francisco, United States
Austin Walne is a Series A investor at Artis Ventures in San Francisco focused on Biotechnology and SaaS. Austin Walne is currently working at ARTIS Ventures, Second Front Systems, and Locus Biosciences.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 71%
Last updated:
For AI agents: llms.txt
Industries Austin Walne invests in
Stages Austin Walne invests in
Countries Austin Walne invests in
Investment Focus
Industry
- Biotechnology 2 (29%)
- SaaS 1 (14%)
- DevOps 1 (14%)
- Medical 1 (14%)
- Oncology 1 (14%)
Stage
- Series A 3 (43%)
- Seed 1 (14%)
- Series B 1 (14%)
- Series C 1 (14%)
Country
- United States 2 (29%)
- Ireland 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Luminate
|
Luminate is an oncology-focused healthtech and tech-enabled services company that partners with payers, providers, and people with cancer to reduce the cost of cancer care while improving quality of life and outcomes for patients. The company offers a portfolio of services and technologies that enable home-based cancer treatment, adverse eventmonitoring, and prevention of drug-induced side effects. | $21M / Series A / Jan 07, 2026 | |
Second Front Systems
|
Second Front Systems (2F) securely fast-tracks government access to software-as-a-service (SaaS) applications to help build a safer tomorrow. The 2F Suite is the only fully integrated platform that empowers you to build, secure, extend, and observe your software, and get it accredited for deployment in regulated environments with ease. With rootsin U.S. Government service, this public-benefit, venture-backed software company is trusted by Government agencies and leading software providers, to empower them to succeed in their contributions to global security. For more information, visit https://secondfront.com/. | $70M / Series C / Sep 13, 2024 | |
|
Luminate
|
Luminate is an oncology-focused healthtech and tech-enabled services company that partners with payers, providers, and people with cancer to reduce the cost of cancer care while improving quality of life and outcomes for patients. The company offers a portfolio of services and technologies that enable home-based cancer treatment, adverse eventmonitoring, and prevention of drug-induced side effects. | $15M / Series A / May 14, 2024 | |
|
Second Front Systems
|
Second Front Systems (2F) securely fast-tracks government access to software-as-a-service (SaaS) applications to help build a safer tomorrow. The 2F Suite is the only fully integrated platform that empowers you to build, secure, extend, and observe your software, and get it accredited for deployment in regulated environments with ease. With rootsin U.S. Government service, this public-benefit, venture-backed software company is trusted by Government agencies and leading software providers, to empower them to succeed in their contributions to global security. For more information, visit https://secondfront.com/. | $32M / Series A / Dec 07, 2022 | |
Locus Biosciences
|
Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment morequickly, resulting in a better medical outcome. | $35M / Series B / May 18, 2022 | |
|
Second Front Systems
|
Second Front Systems (2F) securely fast-tracks government access to software-as-a-service (SaaS) applications to help build a safer tomorrow. The 2F Suite is the only fully integrated platform that empowers you to build, secure, extend, and observe your software, and get it accredited for deployment in regulated environments with ease. With rootsin U.S. Government service, this public-benefit, venture-backed software company is trusted by Government agencies and leading software providers, to empower them to succeed in their contributions to global security. For more information, visit https://secondfront.com/. | $6M / Seed / Jul 07, 2020 | |
|
Locus Biosciences
|
Locus Biosciences is a developer of a CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease. The company's platform combines the antibacterial power of CRISPR-Cas3 with the efficient, safe delivery of bacterial viruses called bacteriophage, enabling physicians to begin treatment morequickly, resulting in a better medical outcome. | $19M / Series A / Nov 14, 2017 |
Co-Investors
About Artis Ventures
ARTIS Ventures is a financial services firm that finances early-to-late-stage venture investments. The team supports its portfolio companies through their entire life cycle, from initial venture investment to public offering and beyond.
Artis Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew McLean
Analyst
|
|||
|
Austin Walne
Partner
|
|||
Henry Klingenstein
Partner
|
|||
Jeff Sheedy
Director of International Marketing
|
|||
Megan Daugherty
Director of Communications and Administration
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Austin Walne invest in?
Austin Walne invests primarily in Biotechnology, SaaS and DevOps startups, most often at Series A and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Austin Walne last invest?
The most recent investment recorded for Austin Walne closed in Jan 2026. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
